Volume | 845,653 |
|
|||||
News | - | ||||||
Day High | 0.99 | Low High |
|||||
Day Low | 0.8801 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Vaxart Inc | VXRT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.99 | 0.8801 | 0.99 | 0.9934 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,384 | 845,653 | US$ 0.9315069 | US$ 787,732 | - | 0.53 - 1.54 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
14:03:39 | 1 | US$ 0.89 | USD |
Vaxart Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
154.74M | 173.86M | - | 7.38M | -82.47M | -0.47 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Vaxart News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VXRT Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.9999 | 1.06 | 0.8431 | 0.9689681 | 1,828,867 | -0.1102 | -11.02% |
1 Month | 0.70 | 1.06 | 0.6331 | 0.8244919 | 1,592,812 | 0.1897 | 27.10% |
3 Months | 1.29 | 1.41 | 0.6331 | 1.01 | 1,604,749 | -0.4003 | -31.03% |
6 Months | 0.71 | 1.54 | 0.53 | 0.9818531 | 1,643,700 | 0.1797 | 25.31% |
1 Year | 1.41 | 1.54 | 0.53 | 0.9185866 | 1,518,451 | -0.5203 | -36.90% |
3 Years | 6.7487 | 10.33 | 0.53 | 4.69 | 2,978,046 | -5.86 | -86.82% |
5 Years | 0.71 | 24.90 | 0.2543 | 6.71 | 6,452,603 | 0.1797 | 25.31% |
Vaxart Description
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. |